ReviewWorld journal of gastroenterology2015
Gastric cancer and the epoch of immunotherapy approaches.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Combined treatment for gastric cancer: Immunological approach.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Trial
- Establishment and validation of a prognostic model based on liquid-liquid phase separation-related genes in gastric cancer.Translational cancer research · 2026Article
- T lymphocyte‑related immune response and immunotherapy in gastric cancer (Review).Oncology letters · 2024Review
- Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model.World journal of gastrointestinal oncology · 2024Article
- Article
- Definition of a Novel Immunogenic Cell Death-Relevant Gene Signature Associated with Immune Landscape in Gastric Cancer.Biochemical genetics · 2023Article
- Immunotherapy for advanced gastric cancer.World journal of methodology · 2023Review
- Identification and validation of anoikis-associated gene SNCG as a prognostic biomarker in gastric cancer.Aging · 2023Article
- Role of microRNA-494 in tumor progression.American journal of translational research · 2023Review
- The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.International journal of cancer · 2022Article
- Gastric cancer cell death analyzed by live cell imaging of spheroids.Scientific reports · 2022Article
- Therapeutic strategies for gastric cancer targeting immune cells: Future directions.Frontiers in immunology · 2022Review
- THBS2 is Closely Related to the Poor Prognosis and Immune Cell Infiltration of Gastric Cancer.Frontiers in genetics · 2022Article
- The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review).Biomedical reports · 2021Review
- Integrated analysis identifies oxidative stress genes associated with progression and prognosis in gastric cancer.Scientific reports · 2021Article
- Identification of Differentially Expressed Genes Reveals BGN Predicting Overall Survival and Tumor Immune Infiltration of Gastric Cancer.Computational and mathematical methods in medicine · 2021Article
- LCP1 is a prognostic biomarker correlated with immune infiltrates in gastric cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- Development and Validation of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and the Immune Microenvironment in Gastric Cancer.BioMed research international · 2021Article
- Early Study of Tumor Abnormal Protein in Gastric Adenocarcinoma.OncoTargets and therapy · 2021Article
- PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study.Translational cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of gastric cancer (GC) fell dramatically over the last 50 years, but according to IARC-Globocan 2008, it is the third most frequent cause of cancer-related deaths with a case fatality GC ratio higher than other common malignancies. Surgical resection is the primary curative treatment for GC though the overall 5-year survival rate remains poor (approximately 20%-25%). To improve the outcome of resectable gastric cancer, different treatment strategies have been evaluated such as adjuvant or perioperative chemotherapy. In resected gastric cancer, the addition of radiotherapy to chemotherapy does not appear to provide any additional benefit. Moreover, in metastatic patients, chemotherapy is the mainstay of palliative therapy with a median overall survival of 8-10 mo and objective response rates of merely 20%-40%. Therefore, the potential for making key beneficial progress is to investigate the GC molecular biology to realize innovative therapeutic strategies, such as specific immunotherapy. In this review, we provide a panoramic view of the different immune-based strategies used for gastric cancer treatment and the results obtained in the most significant clinical trials. In detail, firstly we describe the therapeutic approaches that utilize the monoclonal antibodies while in the second part we analyze the cell-based immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.